Altimmune Inc ALT:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 06/24/22 EDT
10.26quote price arrow up+10.26 (UNCH)
Volume
896,799
Close
10.29quote price arrow down-0.31 (-2.92%)
Volume
6,191,004
52 week range
3.83 - 17.26
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close10.29
  • 52 Week High17.26
  • 52 Week High Date09/13/21
  • 52 Week Low3.83
  • 52 Week Low Date05/12/22

Key Stats

  • Market Cap444.73M
  • Shares Out43.22M
  • 10 Day Average Volume3.23M
  • Dividend-
  • Dividend Yield-
  • Beta0.64
  • YTD % Change12.34

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close10.29
  • 52 Week High17.26
  • 52 Week High Date09/13/21
  • 52 Week Low3.83
  • 52 Week Low Date05/12/22
  • Market Cap444.73M
  • Shares Out43.22M
  • 10 Day Average Volume3.23M
  • Dividend-
  • Dividend Yield-
  • Beta0.64
  • YTD % Change12.34

RATIOS/PROFITABILITY

  • EPS (TTM)-2.41
  • P/E (TTM)-4.26
  • Fwd P/E (NTM)-5.04
  • EBITDA (TTM)-89.503M
  • ROE (TTM)-47.14%
  • Revenue (TTM)3.60M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-2,820.01%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date08/08/2022(est)
  • Ex Div Date02/06/2017
  • Div Amount2.91
  • Split Date-
  • Split Factor-

Latest On Altimmune Inc

There is no recent news for this security.

Profile

MORE
Altimmune, Inc. is a clinical-stage biopharmaceutical company that is focused on developing treatments for obesity and liver diseases. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). It is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic...
Mitchel Sayare Ph.D.
Independent Chairman of the Board
Vipin Garg Ph.D.
President, Chief Executive Officer, Director
Richard Eisenstadt
Chief Financial Officer
Address
910 Clopper Rd Ste 201S
Gaithersburg, MD
20878-1361
United States

Top Peers

SYMBOLLASTCHG%CHG
GERN
Geron Corp
1.37+0.01+0.74%
INO
Inovio Pharmaceuticals Inc
1.94-0.07-3.48%
MRSN
Mersana Therapeutics Inc
5.00+0.09+1.83%
IMGO
Imago BioSciences Inc
13.01+0.18+1.40%
AUTL
Autolus Therapeutics PLC
2.57+0.07+2.80%